According to the Human Genome Project data analyses, only 2% of the human genome is made up of protein-coding genes and 98% is comprised of non-coding genes. Based on the published literature and National Human Genome Research Institute data, there are about 30,000 protein-coding genes and about 60,000 non-coding genes.  

We have identified a set of oncogenic protein-coding genes and non-coding genes that are the drivers for cancer initiation, progression and metastasis. Recent studies have shown that non-coding genes, such as microRNAs (miRNAs) and long-non-coding RNAs (lncRNAs), are involved in regulation of protein-coding genes through direct binding to the 3’UTR of oncogenes or RNA-RNA interactions. We hypothesize that analyses of a set of oncogenic protein-coding genes and non-coding genes are the most promising genetic biomarkers for cancer diagnosis, prognosis, and treatment follow-up.

According to the Cancer Statistics in 2022, about 20 million people worldwide are newly diagnosed with cancer every year in the world and, by 2030, this number is projected to be doubled if not controlled. The major problem is the lack of testing for early diagnosis, prognosis and monitoring of treatment follow-up. In some South East Asian countries, such as India, about 40% of cancer patients are metastatic at the time of diagnosis due to lack of testing. Almost all cancer patients die of metastasis and, presently, there is no effective therapy for metastatic cancer. Our professionals at GeneVerify, Inc., believe it is crucial to early identification and intervention that targeting a set of oncogenes can inhibit cancer progression and metastasis. These state of the art technologies will thereby improving patient outcomes while, at the same time, lowering healthcare costs.

Precision medicine is based on genetic profiling of a set of tumors. Based on the published literature, one in five patients that are newly diagnosed have different genetic profiling and, thus, one drug does not fit all.  Therefore, gene-based diagnosis and therapy will absolutely transform and revolutionize the field.

 Based on the published literature, about 35% of cancer patients that are normal by histology and clinical assessment have, in fact, early stage cancer based on their genetic profile. Our team of scientists at GeneVerify are developing innovative, gene-based testing for early diagnosis, prognosis and monitoring treatment, as well as gene-based treatments for various cancers.

We have assembled a highly talented team of molecular biologists, cell biologists, biochemists, pathologists, urologists, surgical oncologists, medical oncologists, radiation oncologists, physicians and surgeons that will address the gene-based diagnosis and treatment of various solid tumors. 

We rationalize that altered expression of these sets of oncogenic protein- coding genes and non- coding genes can be used for early diagnosis, prognosis, risk assessment of individualized therapeutic intervention, and treatment follow-up for various cancers. We expect that targeting these genes will revolutionize the treatment of these cancers. These are the most powerful research technologies that can save the lives of millions of people.

GeneVerify, Inc., provides in vitro diagnostic reagents for research laboratory-based assays for analysis of sets of these oncogenic protein-coding and non-coding genes in various cancers. Our extensive network of colleagues is committed to developing novel technologies to target these genes with the goal to provide the path to the most effective and highly specific, individualized, treatment for various cancers. GeneVerify’s targeted genetic testing kits are the path to value-based rapid testing, discovery and identification, and risk prediction that is invaluable to early intervention.

Backed by our genetic testing profiling, medical oncologists and surgical oncologists may enable to (i) diagnose early stage cancer (ii) predict whether tumor is aggressive or slow growing and thus provide better decisions for surgery or active surveillance (iii) predict prognosis and risk assessment of cancer based on genetic profiling (iv) better predict how a patient might respond to certain modalities and therapies more accurately, and (v) achieve a solid basis for better decision-making on a patient’s therapeutic treatment and future evaluation to yield the quickest results, thereby enhancing your patient’s health, lengthen life, and reduce illness and disability.

 At GeneVerify, Inc., we are tackling the issues that matter most to patient care in a collaborative setting where teamwork and innovation leads to more answers.